CA2383491A1 - Large porous particles by spray-drying - Google Patents
Large porous particles by spray-drying Download PDFInfo
- Publication number
- CA2383491A1 CA2383491A1 CA002383491A CA2383491A CA2383491A1 CA 2383491 A1 CA2383491 A1 CA 2383491A1 CA 002383491 A CA002383491 A CA 002383491A CA 2383491 A CA2383491 A CA 2383491A CA 2383491 A1 CA2383491 A1 CA 2383491A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- salt
- microns
- phospholipid
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15066299P | 1999-08-25 | 1999-08-25 | |
| US60/150,662 | 1999-08-25 | ||
| PCT/US2000/023118 WO2001013892A2 (en) | 1999-08-25 | 2000-08-23 | Large porous particles by spray-drying |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2383491A1 true CA2383491A1 (en) | 2001-03-01 |
Family
ID=22535487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002383491A Abandoned CA2383491A1 (en) | 1999-08-25 | 2000-08-23 | Large porous particles by spray-drying |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1210069B1 (enExample) |
| JP (1) | JP2003507411A (enExample) |
| AT (1) | ATE285755T1 (enExample) |
| AU (1) | AU768299B2 (enExample) |
| CA (1) | CA2383491A1 (enExample) |
| DE (1) | DE60017152D1 (enExample) |
| WO (1) | WO2001013892A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| PT1280520E (pt) * | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US6848197B2 (en) * | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| JP2004528339A (ja) * | 2001-04-26 | 2004-09-16 | ネクター セラピューティクス | 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物 |
| GB0120123D0 (en) * | 2001-08-17 | 2001-10-10 | Upperton Ltd | Preparation of microparticles |
| CA2465779A1 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
| ES2364636T3 (es) | 2001-12-19 | 2011-09-08 | Novartis Ag | Administración pulmonar de aminoglucósidos. |
| AU2003287132B2 (en) * | 2002-12-13 | 2009-03-12 | Adagit | Pharmaceutical porous particles |
| JP2012522009A (ja) * | 2009-03-26 | 2012-09-20 | パルマトリックス,インコーポレイテッド | 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法 |
| RU2577698C2 (ru) | 2009-03-26 | 2016-03-20 | Пулмэтрикс, Инк. | Сухие порошкообразные составы и способы лечения легочных заболеваний |
| CA2809666C (en) * | 2010-08-30 | 2020-09-22 | Michael M. Lipp | Dry powder formulations and methods for treating pulmonary diseases |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| ES2710537T3 (es) * | 2010-09-29 | 2019-04-25 | Pulmatrix Operating Co Inc | Polvos secos catiónicos |
| RU2640921C2 (ru) | 2010-09-29 | 2018-01-12 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| CA2865972C (en) | 2012-02-29 | 2022-01-04 | Pulmatrix, Inc. | Inhalable dry powders |
| MX2015013845A (es) | 2013-04-01 | 2016-05-09 | Pulmatrix Inc | Polvos secos de tiotropio. |
| AU2015213678C1 (en) | 2014-02-10 | 2019-03-21 | Respivant Sciences Gmbh | Mast cell stabilizers treatment for systemic disorders |
| EP3104854B1 (en) | 2014-02-10 | 2020-04-08 | Respivant Sciences GmbH | Mast cell stabilizers for lung disease treatment |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| CA3133804A1 (en) * | 2019-03-22 | 2020-10-01 | Mannkind Corporation | Inhalable dry powders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| WO1997026863A1 (de) * | 1996-01-24 | 1997-07-31 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| EP0954282B1 (en) * | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
-
2000
- 2000-08-23 EP EP00959327A patent/EP1210069B1/en not_active Expired - Lifetime
- 2000-08-23 JP JP2001518030A patent/JP2003507411A/ja not_active Withdrawn
- 2000-08-23 DE DE60017152T patent/DE60017152D1/de not_active Expired - Lifetime
- 2000-08-23 AT AT00959327T patent/ATE285755T1/de not_active IP Right Cessation
- 2000-08-23 AU AU70666/00A patent/AU768299B2/en not_active Ceased
- 2000-08-23 WO PCT/US2000/023118 patent/WO2001013892A2/en not_active Ceased
- 2000-08-23 CA CA002383491A patent/CA2383491A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1210069A2 (en) | 2002-06-05 |
| EP1210069B1 (en) | 2004-12-29 |
| AU768299B2 (en) | 2003-12-04 |
| DE60017152D1 (de) | 2005-02-03 |
| WO2001013892A3 (en) | 2001-06-21 |
| WO2001013892A2 (en) | 2001-03-01 |
| AU7066600A (en) | 2001-03-19 |
| JP2003507411A (ja) | 2003-02-25 |
| ATE285755T1 (de) | 2005-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7807200B2 (en) | Formulations for spray-drying large porous particles | |
| CA2382651C (en) | Use of simple amino acids to form porous particles | |
| EP1210069B1 (en) | Large porous particles obtainable by spray-drying and suitable for pulmonary administration | |
| CA2341624C (en) | Stable spray-dried protein formulations | |
| US7252840B1 (en) | Use of simple amino acids to form porous particles | |
| US20060002996A1 (en) | Stable spray-dried protein formulations | |
| EP1210067A2 (en) | Modulation of release from dry powder formulations | |
| WO2002067902A2 (en) | Modulation of release from dry powder formulations | |
| AU2002242253A1 (en) | Modulation of release from dry powder formulations | |
| EP1345629A2 (en) | Particles for inhalation having sustained release properties | |
| WO2002078675A2 (en) | Particles for inhalation having sustained release properties | |
| EP1767195A2 (en) | Stable spray-dried protein formulations | |
| HK1101138A (en) | Stable spray-dried protein formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |